Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Oct 16

PMID 30319626

Citations 94

Authors

Aifen Lin

Wei-Hua Yan

Affiliations

Soon will be listed here.

Abstract

Phenotypic heterogeneity has been observed in most malignancies, which represents a considerable challenge for tumor therapy. In recent decades, the biological function and clinical significance of the human leukocyte antigen (HLA)-G have been intensively explored. It is now widely accepted that HLA-G is a critical marker of immunotolerance in cancer cell immune evasion and is strongly associated with disease progress and prognosis for cancer patients. Moreover, it has recently been emphasized that the signaling pathway linking HLA-G and immunoglobulin-like transcripts (ILTs) is considered an immune checkpoint. In addition, HLA-G itself can generate at least seven distinct isoforms, and intertumor and intratumor heterogeneity of HLA-G expression is common across different tumor types. Furthermore, HLA-G heterogeneity in cancers has been related to disease stage and outcomes, metastatic status and response to different therapies. This review focuses on the heterogeneity of HLA-G expression in malignant lesions, and clinical implications of this heterogeneity that might be relevant to personalized treatments are also discussed.

Citing Articles

JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G.

Obermajer N, Zwolak A, van de Ven K, Versmissen S, Menard K, Rogers K iScience. 2025; 28(3):111876.

PMID: 40060890 PMC: 11889666. DOI: 10.1016/j.isci.2025.111876.

Targeting of Non-Classical Human Leukocyte Antigens as Novel Therapeutic Strategies in Cancer.

Benitez Fuentes J, Bartolome Arcilla J, Mohamed Mohamed K, Lopez de Sa A, de Luna Aguilar A, Guevara-Hoyer K Cancers (Basel). 2025; 16(24.

PMID: 39766165 PMC: 11675049. DOI: 10.3390/cancers16244266.

Emerging strategies to overcome ovarian cancer: advances in immunotherapy.

Massariol Pimenta T, Carlos de Souza J, da Silva Martins B, Silva Butzene S, Simoes Padilha J, Ganho Marcal M Front Pharmacol. 2024; 15:1490896.

PMID: 39564107 PMC: 11573523. DOI: 10.3389/fphar.2024.1490896.

HLA-G high-expressor 3'UTR markers are linked to gastric cancer development and survival.

Vaquero-Yuste C, Juarez I, Molina-Alejandre M, Molanes-Lopez E, Gutierrez-Calvo A, Lopez-Garcia A Cancer Immunol Immunother. 2024; 74(1):26.

PMID: 39549048 PMC: 11569108. DOI: 10.1007/s00262-024-03771-w.

HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance.

Branz A, Matek C, Lange F, Bahlinger V, Klumper N, Holzel M Front Immunol. 2024; 15:1478196.

PMID: 39469714 PMC: 11513269. DOI: 10.3389/fimmu.2024.1478196.

References

Menter T, Tzankov A . Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells. Front Oncol. 2018; 8:54. PMC: 5845888. DOI: 10.3389/fonc.2018.00054. View

Yan W, Liu D, Lu H, Li Y, Zhang X, Lin A . Significance of tumour cell HLA-G5/-G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients. J Cell Mol Med. 2015; 19(4):778-85. PMC: 4395192. DOI: 10.1111/jcmm.12400. View

Ramos C, Goncalves A, Marinho L, Avelino M, Saddi V, Lopes A . Analysis of HLA-G gene polymorphism and protein expression in invasive breast ductal carcinoma. Hum Immunol. 2014; 75(7):667-72. DOI: 10.1016/j.humimm.2014.04.005. View

Lin A, Xu H, Xu D, Zhang X, Wang Q, Yan W . Multiple steps of HLA-G in ovarian carcinoma metastasis: alter NK cytotoxicity and induce matrix metalloproteinase-15 (MMP-15) expression. Hum Immunol. 2012; 74(4):439-46. DOI: 10.1016/j.humimm.2012.11.021. View

Morandi F, Rouas-Freiss N, Pistoia V . The emerging role of soluble HLA-G in the control of chemotaxis. Cytokine Growth Factor Rev. 2014; 25(3):327-35. DOI: 10.1016/j.cytogfr.2014.04.004. View

Xu Y, Lu Y, Cheng H, Jiang J, Xu J, Long J . High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC. Curr Mol Med. 2015; 15(4):360-7. DOI: 10.2174/1566524015666150401102218. View

Nunes L, Ayres F, Francescantonio I, Saddi V, Avelino M, Alencar R . Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer. Hum Immunol. 2012; 74(4):447-51. DOI: 10.1016/j.humimm.2012.12.012. View

Carosella E, Gregori S, Rouas-Freiss N, LeMaoult J, Menier C, Favier B . The role of HLA-G in immunity and hematopoiesis. Cell Mol Life Sci. 2010; 68(3):353-68. PMC: 11114977. DOI: 10.1007/s00018-010-0579-0. View

Rajagopalan S, Long E . KIR2DL4 (CD158d): An activation receptor for HLA-G. Front Immunol. 2012; 3:258. PMC: 3422731. DOI: 10.3389/fimmu.2012.00258. View

10.

Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U . Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001; 92(2):369-76. DOI: 10.1002/1097-0142(20010715)92:2<369::aid-cncr1332>3.0.co;2-u. View

11.

Howangyin K, Alegre E, Daouya M, Favier B, Carosella E, LeMaoult J . Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cell Mol Life Sci. 2010; 67(7):1133-45. PMC: 11115494. DOI: 10.1007/s00018-009-0239-4. View

12.

Swets M, Konig M, Zaalberg A, Dekker-Ensink N, Gelderblom H, van de Velde C . HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases. Hum Immunol. 2016; 77(9):773-9. DOI: 10.1016/j.humimm.2016.03.001. View

13.

Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R . HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood. 2002; 99(2):609-17. DOI: 10.1182/blood.v99.2.609. View

14.

Agaugue S, Carosella E, Rouas-Freiss N . Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood. 2011; 117(26):7021-31. DOI: 10.1182/blood-2010-07-294389. View

15.

Grange C, Tapparo M, Tritta S, Deregibus M, Battaglia A, Gontero P . Role of HLA-G and extracellular vesicles in renal cancer stem cell-induced inhibition of dendritic cell differentiation. BMC Cancer. 2015; 15:1009. PMC: 4690241. DOI: 10.1186/s12885-015-2025-z. View

16.

Lee C, Guo Y, So K, Vijayan M, Guo Y, Wong V . Soluble human leukocyte antigen G5 polarizes differentiation of macrophages toward a decidual macrophage-like phenotype. Hum Reprod. 2015; 30(10):2263-74. DOI: 10.1093/humrep/dev196. View

17.

de Figueiredo Feitosa N, Crispim J, Zanetti B, Magalhaes P, Soares C, Soares E . HLA-G is differentially expressed in thyroid tissues. Thyroid. 2013; 24(3):585-92. DOI: 10.1089/thy.2013.0246. View

18.

Kleinberg L, Florenes V, Skrede M, Dong H, Nielsen S, McMaster M . Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 2006; 449(1):31-9. DOI: 10.1007/s00428-005-0144-7. View

19.

Zhang X, Han Q, Li J, Ruan Y, Yan W, Lin A . Lesion HLA-G5/-G6 isoforms expression in patients with ovarian cancer. Hum Immunol. 2015; 77(9):780-4. DOI: 10.1016/j.humimm.2015.12.003. View

20.

Lesport E, Baudhuin J, Sousa S, LeMaoult J, Zamborlini A, Rouas-Freiss N . Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell Mol Life Sci. 2011; 68(20):3385-99. PMC: 11114898. DOI: 10.1007/s00018-011-0632-7. View